Aged Tgfbeta2/Gdnf double-heterozygous mice show no morphological and functional alterations in the nigrostriatal system.
Loss of dopaminergic neurons in the substantia nigra pars compacta and the resulting decrease in striatal dopamine levels are the hallmarks of Parkinson's disease. Tgfbeta and Gdnf have been identified as neurotrophic factors for dopaminergic midbrain neurons in vivo and in vitro. Haploinsufficiency for either Tgfbeta or Gdnf led to dopaminergic deficits. In this study we therefore analyzed the nigrostriatal system of aged Tgfbeta2 (+/-)/Gdnf (+/-) double-heterozygous mice. Unexpectedly, we found no morphological changes in the nigrostriatal system as compared with age-matched wild-type mice. There were no significant differences in the number of TH-positive midbrain neurons and no changes in the optical density of TH immunoreactivity in striata of Tgfbeta2 (+/-)/Gdnf (+/-) double-heterozygous mice. Moreover, we found no significant differences in the striatal levels of dopamine and its metabolites dihydroxyphenylacetic acid and homovanillic acid. Our results indicate that a combined haploinsufficiency for Tgfbeta2 and Gdnf has no impact on the function and the survival of midbrain DA neurons under normal aging conditions.
Heermann
Stephan
S
Department of Molecular Embryology, Institute of Anatomy and Cell Biology, Albert-Ludwigs-University Freiburg, Freiburg, Germany. stephan.heermann@zoo.uni-heidelberg.de
Opazo
Felipe
F
Falkenburger
Björn
B
Krieglstein
Kerstin
K
Spittau
Björn
B
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000375:Aging; D000704:Analysis of Variance; D000818:Animals; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D003342:Corpus Striatum / Q000473:pathology*; D004298:Dopamine / Q000378:metabolism; D004563:Electrochemistry / Q000379:methods; D005786:Gene Expression Regulation / Q000235:genetics*; D051100:Glial Cell Line-Derived Neurotrophic Factor / Q000172:deficiency / Q000235:genetics*; D006719:Homovanillic Acid / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D009434:Neural Pathways / Q000473:pathology; D012333:RNA, Messenger / Q000378:metabolism; D013378:Substantia Nigra / Q000473:pathology*; D053781:Transforming Growth Factor beta2 / Q000172:deficiency / Q000235:genetics*; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
C495040:Gdnf protein, mouse; D051100:Glial Cell Line-Derived Neurotrophic Factor; D012333:RNA, Messenger; C509042:Tgfb2 protein, mouse; D053781:Transforming Growth Factor beta2; D015102:3,4-Dihydroxyphenylacetic Acid; D014446:Tyrosine 3-Monooxygenase; D004298:Dopamine; D006719:Homovanillic Acid
J Neurosci. 2006 Oct 25;26(43):11230-8
17065462
Neuroscience. 1994 Dec;63(4):1189-96
7700516
PLoS Biol. 2007 Mar;5(3):e39
17298183
EMBO J. 1995 Feb 15;14(4):736-42
7882977
J Comp Neurol. 1995 May 15;355(4):479-89
7636027
J Neurosci. 2003 Jun 15;23(12):5178-86
12832542
Int J Dev Neurosci. 2009 Feb;27(1):97-102
18824086
Brain Res. 1995 Feb 20;672(1-2):104-11
7749731
J Neurosci. 1998 Dec 1;18(23):9822-34
9822741
Neurobiol Dis. 2007 Feb;25(2):378-91
17141511
J Cell Biol. 2002 Oct 14;159(1):157-67
12370242
Neurobiol Dis. 2006 Mar;21(3):568-75
16257223
Neuron. 2003 Sep 11;39(6):889-909
12971891
Nature. 1995 Jan 26;373(6512):335-9
7830766
J Histochem Cytochem. 1981 Jun;29(6):775
7252134
Science. 1993 May 21;260(5111):1130-2
8493557
Development. 1997 Jul;124(13):2659-70
9217007
Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8935-9
7568047
Nature. 1996 Jul 4;382(6586):73-6
8657307
Science. 2000 Oct 27;290(5492):767-73
11052933
Exp Neurol. 2006 Dec;202(2):336-47
16889771
Stem Cells. 2008 Jul;26(7):1683-94
18420832
Neurosci Lett. 1994 Nov 21;182(1):107-11
7891873
Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20049-54
18056810
APMIS. 1988 Oct;96(10):857-81
3056461
Nature. 1996 Jul 4;382(6586):70-3
8657306